Teva settles Israeli tax dispute for ~$750M over 2008-2020, plus up to $500M contingent

TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva to pay ~$750M to Israeli Tax Authorities over 2024-2029 for tax years 2008-2020.
Includes ~$500M corporate taxes on previously tax-exempt earnings under Encouragement for Capital Investment Law.
Additional ~$250M for other disputed tax issues in the same period.
Contingent payment of 5%-7% of future dividends/repurchases, capped at ~$500M.
Settlement ends litigation with ITA over historical tax years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.